Fentanyl information center
Sandoz and Novartis confirm receipt of EU Statement of Objection
Sandoz B.V., a subsidiary of Novartis, and Novartis have received on Jan. 31st a Statement of Objections from the European Commission in relation to the Commission's Fentanyl investigation in which formal proceedings were initiated in October 2011.
The Statement of Objections relates to the Commission’s investigation regarding the activities of Sandoz B.V. concerning Fentanyl in the Netherlands from July 2005 until December 2006.
The Statement of Objections contains the Commission’s preliminary view with respect to an agreement on Fentanyl. Its purpose is to allow addressees the opportunity to comment on the factual and legal issues that led the Commission to believe that an infringement of the EU competition rules may have occurred. The sending of a Statement of Objections does not prejudge the final outcome of the investigation.
Sandoz and Novartis operate to the highest of standards and take the position of the Commission seriously. They will closely examine the Statement of Objections and will avail themselves of their rights of defense as provided for in the process.
